Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Anat Globerson-Levin"'
Autor:
Julia Sajman, Oren Yakovian, Naamit Unger Deshet, Shaked Almog, Galit Horn, Tova Waks, Anat Globerson Levin, Eilon Sherman
Publikováno v:
Cells, Vol 12, Iss 18, p 2261 (2023)
T cells expressing chimeric antigen receptors (CARs) are at the forefront of clinical treatment of cancers. Still, the nanoscale organization of CARs at the interface of CAR-Ts with target cells, which is essential for TCR-mediated T cell activation,
Externí odkaz:
https://doaj.org/article/f22b6b80cb944a8d85fae3569995e08d
Autor:
Liat Rousso-Noori, Ignacio Mastandrea, Shauli Talmor, Tova Waks, Anat Globerson Levin, Maarja Haugas, Tambet Teesalu, Luis Alvarez-Vallina, Zelig Eshhar, Dinorah Friedmann-Morvinski
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
Chimeric antigen receptor (CAR) T cell therapy has been proposed as a promising approach for treating glioblastoma. Here the authors show that p32 is expressed in murine and human glioma and that p32-directed CAR-T cells promote anti-tumor responses
Externí odkaz:
https://doaj.org/article/c9d019d611994e5cb582be3f41cb6a8b
Autor:
Naamit Deshet-Unger, Galit Horn, Moran Rawet-Slobodkin, Tova Waks, Ido Laskov, Nadav Michaan, Yael Raz, Vered Bar, Adi Zundelevich, Sara Aharon, Lubov Turovsky, Giuseppe Mallel, Seth Salpeter, Guy Neev, Kenneth Samuel Hollander, Ben-Zion Katz, Dan Grisaru, Anat Globerson Levin
Publikováno v:
Biomedicines, Vol 10, Iss 9, p 2216 (2022)
High-grade serous ovarian carcinoma (HGSOC) is the most common type of epithelial ovarian cancer. The majority of cases are diagnosed at advanced stages, when intraperitoneal (IP) spread has already occurred. Despite significant surgical and chemothe
Externí odkaz:
https://doaj.org/article/16dbc1696e5e4daea159f67c152a7d9b
Autor:
Yamit Shorer Arbel, Ben-Zion Katz, Ronen Gabizon, Amit Shraga, Yotam Bronstein, Talia Kamdjou, Anat Globerson Levin, Chava Perry, Irit Avivi, Nir London, Yair Herishanu
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Proteolysis targeting chimeras (PROTACs) are small molecules that form ternary complexes between their target and E3 ligase, resulting in ubiquitination and proteasomal degradation of the target protein. Using our own designed Bruton’s tyrosine kin
Externí odkaz:
https://doaj.org/article/650b70fb17db4836a1e4c93f379c112c
Autor:
Alexander Levitzki, Mark X. Sliwkowski, Anat Globerson Levin, Gabriel Mizraji, Shang-Fan Yu, Jeffrey Lau, Nufar Edinger, Shoshana Klein, Anna Sagalov, Salim Joubran, Alexei Shir, Maya Zigler
Supplementary Material and methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ba8b54e7bdb6781ac551d6c860fe44e
https://doi.org/10.1158/2326-6066.22538000.v1
https://doi.org/10.1158/2326-6066.22538000.v1
Autor:
Alexander Levitzki, Mark X. Sliwkowski, Anat Globerson Levin, Gabriel Mizraji, Shang-Fan Yu, Jeffrey Lau, Nufar Edinger, Shoshana Klein, Anna Sagalov, Salim Joubran, Alexei Shir, Maya Zigler
The development of targeted therapies that affect multiple signaling pathways and stimulate antitumor immunity is greatly needed. About 20% of patients with breast cancer overexpress HER2. Small molecules and antibodies targeting HER2 convey some sur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e4fb8c734f4b546b57e4f28878440a6
https://doi.org/10.1158/2326-6066.c.6548633.v1
https://doi.org/10.1158/2326-6066.c.6548633.v1
Autor:
Alexander Levitzki, Mark X. Sliwkowski, Anat Globerson Levin, Gabriel Mizraji, Shang-Fan Yu, Jeffrey Lau, Nufar Edinger, Shoshana Klein, Anna Sagalov, Salim Joubran, Alexei Shir, Maya Zigler
Supplementary Figure illustrating the difference in cytokine mRNA and protein expression following treatment of BT-474 with pIC/PPHAffibody and pIC/PPCys
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67253c4e105aeefd9eb88b5d1004811b
https://doi.org/10.1158/2326-6066.22538006.v1
https://doi.org/10.1158/2326-6066.22538006.v1
Autor:
Tamar Shiloach, Marina Roitman, Lital Gasri Plotnitsky, Hadar Simchony Goldman, Ilan Volovitz, Oz Haim, Zvi Ram, Anat Globerson-Levin, Niv Pencovich, Zelig Eshhar, Rachel Grossman, Gil Diamant
Publikováno v:
The Journal of Immunology. 207:709-719
Tumor-treating fields (TTFields) are a localized, antitumoral therapy using alternating electric fields, which impair cell proliferation. Combining TTFields with tumor immunotherapy constitutes a rational approach; however, it is currently unknown wh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a296741dd98033fae76d10674f106c5
https://doi.org/10.4049/jimmunol.2100100
https://doi.org/10.4049/jimmunol.2100100
Autor:
Ido Laskov, Naamit Deshet-Unger, Tova Waks, Nadav Michaan, Yael Raz, Ben-Zion Katz, Dan Grisaru, Anat Globerson Levin
Publikováno v:
Gynecologic Oncology. 166:S164
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a19f7330b246e414aa2390419b1cd3f8
https://doi.org/10.1016/s0090-8258(22)01536-0
https://doi.org/10.1016/s0090-8258(22)01536-0
Autor:
Eva Zupancic, Tova Waks, Ronit Satchi-Fainaro, Eilam Yeini, Ziv Porat, Anat Globerson-Levin, Caterina Curato, João Nuno Moreira, Steffen Jung, Lea Eisenbach, Ana S. Viana, Zelig Eshhar, Jung-Seok Kim, Helena F. Florindo
Publikováno v:
Nanomedicine: Nanotechnology, Biology and Medicine. 14:835-847
Nanoparticulate vaccines are promising tools to overcome cancer immune evasion. However, a deeper understanding on nanoparticle-immune cell interactions and treatments regime is required for optimal efficacy. We provide a comprehensive study of treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba0eacb0e5deae167c04ba7d3c825c55
https://doi.org/10.1016/j.nano.2017.12.011
https://doi.org/10.1016/j.nano.2017.12.011